Jeannette Y. Wick, RPh, MBA, FASCP

Although antiretroviral therapy has led to significantly longer life expectancies among individuals with HIV, this, in turn, has contributed to the likelihood that these individuals will develop age-related comorbidities at earlier ages.

Clinicians should counsel individuals with HIV on avoiding health-related behaviors that may alter their gut microbiota and instead practices those that may decrease inflammation.

Case Western Reserve University School of Medicine researchers identify accentuated risks for age-associated comorbidities in those living with HIV.

A systematic review analyzes the opportunity to provide coordinated care for HIV and noncommunicable conditions.

A group of researchers examine the feasibility of a low-resource behavioral intervention created to promote retention in HIV care.

Patients who have HCV infection are at high risk for arthralgia, myalgias, pruritus, neuropathy, and decompensated livers. Until recently the sole available treatment was interferon. After the US Food and Drug Administration (FDA) approved ribavirin, patients who took ribavirin plus interferon responded better. Now, the FDA has approved a small selection of oral antivirals to treat hepatitis C.